Jane L. Halpern, PhD IAVI

Jane Halpern, PhD, is Executive Director of Regulatory Affairs at IAVI.

Dr. Halpern has over 25 years of experience in biologics development and has held positions in government as well as both small and large biotech companies. She worked at the FDA, Center for Biologics Evaluation and Research (CBER) as a researcher/reviewer for 10 years where she reviewed applications for both investigational and commercial products.

Dr. Halpern has held senior management positions at ID Biomedical Corporation, GSK Biologics, and Novavax Inc. At ID Biomedical Corporation, she led the global regulatory team that was responsible for obtaining FDA accelerated approval of a seasonal influenza vaccine and that supported the acquisition of ID Biomedical by GSK. She has experience with all stages of product development from newly discovered entities to lifecycle management of licensed products.

Dr. Halpern currently serves as a co-chair of the PDA Vaccine Interest Group and is a member of the Regulatory Affairs/Quality Assurance Advisory Board for PDA. She received her BS in Physiology from the University of California, Davis and her PhD in Pharmacology from the University of Rochester.